Normal view MARC view ISBD view

Helminths of sympatric populations of kangaroo rats (Dipodomys ordii) and grasshopper mice (Onychomys leucogaster) from the high plains of eastern New Mexico. [electronic resource]

By:

Pfaffenberger, G S

Contributor(s):

Producer: 19851213Description: 592-5 p. digitalISSN:

0022-3395

Subject(s):

In: The Journal of parasitology vol. 71

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Journal Article; Research Support, Non-U.S. Gov't

There are no comments on this title.

to post a comment.

Back to results

1 Early Pharmacodynamic Effects of Exenatide Once Weekly in Type 2 Diabetes Are Independent of Weight Loss: A Pooled Analysis of Patient-level Data.
by Trautmann, Michael E
2 Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery.
by Carpenter, Thomas
3 Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.
by Parkes, David G
4 Three-year efficacy and safety of exenatide once weekly: A pooled analysis of three trials.
by Trautmann, Michael E
5 Assessment of pancreatic β-cell function: review of methods and clinical applications.
by Cersosimo, Eugenio
6 Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study.
by Guerci, Bruno
7 Safety of exenatide once weekly in patients with type 2 diabetes mellitus treated with a thiazolidinedione alone or in combination with metformin for 2 years.
by Norwood, Paul
8 Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
by Keller, Jutta
9 Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
by Barnett, Anthony H
10 Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
by Wysham, Carol H
11 Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes.
by Yoon, Kun-Ho
12 Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
by Diamant, Michaela
13 Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.
by Del Prato, Stefano
14 Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes.
by Linnebjerg, Helle
15 Body weight management and safety with efpeglenatide in adults without diabetes: A phase II randomized study.
by Pratley, Richard E
16 The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
by Zinman, Bernard
17 Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide.
by Rosenstock, Julio